Bio-Rad's blood-based immunoassay test can help clinicians identify if an individual has developed antibodies against SARS-CoV-2, the virus associated with COVID-19
Bio-Rad offers a portfolio of recombinant, monoclonal anti-idiotypic antibodies and drug-target complex binders for the development of highly selective and sensitive assays
The new product line includes a real-time RT-PCR assay to screen for infected individuals and immunodiagnostic tests for IgM and IgG COVID-19 antibodies
Intended for calibration, or calibration verification, these versatile products are expressly designed to support overall system QC and CLIA compliance